e-learning
resources
Stockholm 2007
Wednesday 19.09.2007
XDR-Tuberculosis: a new threat
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
XDR-tuberculosis prevention and control
P. Hopewell (San Francisco, United States of America)
Source:
Annual Congress 2007 - XDR-Tuberculosis: a new threat
Session:
XDR-Tuberculosis: a new threat
Session type:
Hot topics
Number:
4209
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Hopewell (San Francisco, United States of America). XDR-tuberculosis prevention and control. Annual Congress 2007 - XDR-Tuberculosis: a new threat
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Challenges in the prevention, diagnosis, and treatment of tuberculosis in children
Source: International Congress 2019 – Tuberculosis: latest advances and challenges in patient management
Year: 2019
Evolution of TB control and elimination strategies
Source: School Course 2012 - TB and M/XDR-TB: from clinical management to control and elimination
Year: 2012
Strategies against multidrug-resistant tuberculosis
Source: Eur Respir J 2002; 20: 66S-77S
Year: 2002
Access and adherence to tuberculosis prevention and care for hard-to-reach groups
Source: Eur Respir Monogr 2018; 82: 291-307
Year: 2018
Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB
Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis
Year: 2007
Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015
Bedaquiline-containing regimens for MDR TB treatment – Focus on the safety
Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline
Year: 2016
Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases
Source: Eur Respir J, 50 (1) 1700648; 10.1183/13993003.00648-2017
Year: 2017
Current approaches to the prevention of tuberculosis in patients receiving immunosuppressants
Source: Virtual Congress 2021 – Epidemiological aspects of tuberculosis
Year: 2021
Interventions to improve retention-in-care and treatment adherence among patients with drug-resistant tuberculosis: a systematic review
Source: Eur Respir J, 53 (1) 1801030; 10.1183/13993003.01030-2018
Year: 2019
Effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug resistant tuberculosis
Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments
Year: 2016
Immunological response in HIV-associated tuberculosis and the implications of HIV in the search for a tuberculosis vaccine
Source: Annual Congress 2007 - Tuberculosis control and HIV in Europe: good or bad news?
Year: 2007
Prevention of TB in areas of high incidence
Source: Eur Respir Mon 2012; 58: 84-94
Year: 2012
All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings
Source: Eur Respir J, 59 (1) 2004345; 10.1183/13993003.04345-2020
Year: 2022
The effectiveness of the national program tuberculosis control in Ukraine and the future strategy
Source: Eur Respir J 2006; 28: Suppl. 50, 130s
Year: 2006
Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use
Source: Eur Respir J, 50 (1) 1700311; 10.1183/13993003.00311-2017
Year: 2017
MDR-TB and XDR-TB: drug resistance and treatment outcomes
Source: Eur Respir J 2009; 34: 778
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept